As an aside, there is debate regarding prostate-specific antigen (PSA) screening for prostate cancer, with current recommendations emphasizing shared decision-making.18 An explanation for our prostate cancer-specific results may be that greater adherence to annual PCP use may allow for better risk-stratification and shared-decision making for initiating PSA screening in higher risk patients. This evidence concerns the gene KLK3 and Familial prostate cancer.